Company Overview and News

4
Alphabet: Playing A Dangerous Game

2018-10-11 seekingalpha
The Google CEO meeting with the White House later this month is crucial to removing regulatory risks from search and self-driving cars.
GOOGL TAC AAPL

 
TAC / TransAlta Corporation FORM 6-K (Current Report of Foreign Issuer)

2018-10-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TAC

 
TAC / TransAlta Corporation FORM 6-K (Current Report of Foreign Issuer)

2018-10-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TAC

 
Court blocks FMG report access

2018-10-01 businessnews.com.au
Fortescue Metals Group has failed to get its hands on a crucial engineering report at the heart of a legal dispute with Canadian company TransAlta Corporation.
FSUMF TAC FMG FSUGY

1
Dividend 15 Split Corp. Declares 174th Consecutive Monthly Distribution

2018-09-19 globenewswire
TORONTO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. declares its 174th consecutive monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04375 for each Preferred share ($0.525 annually). Distributions are payable October 10, 2018 to shareholders on record as at September 28, 2018.
SLF TAC CIFAF TD BCE TD TRP TNTTF SLF MFC 0945 CIX TRI MFC SLFYF TU SLF

1
Dividend 15 Split Corp. II Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-08-20 globenewswire
TORONTO, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. II ("Dividend 15 II") declares its regular monthly distribution of $0.10000 for each Class A share and $0.04375 for each Preferred share. The net asset value at the time of declaration was $15.10. Distributions are payable September 10, 2018 to shareholders on record as at August 31, 2018.
SLF TAC CIFAF TD BCE TD TRP TNTTF DF SLF MFC 0945 CIX TRI MFC SLFYF TU SLF

1
Dividend 15 Split Corp. Declares 173rd Consecutive Monthly Distribution

2018-08-20 globenewswire
TORONTO, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. declares its 173rd consecutive monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04375 for each Preferred share ($0.525 annually). Distributions are payable September 10, 2018 to shareholders on record as at August 31, 2018.
SLF TAC CIFAF TD BCE TD TRP TNTTF SLF MFC 0945 CIX TRI MFC SLFYF TU SLF

 
PRESS DIGEST -Canada - Aug 6

2018-08-06 reuters
Aug 6 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
TAC

 
TransAlta Corporation 2018 Q2 - Results - Earnings Call Slides

2018-08-04 seekingalpha
The following slide deck was published by TransAlta Corporation in conjunction with their 2018 Q2 earnings call.
TAC

 
TransAlta Corporation (TAC) CEO Dawn Farrell on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good morning. My name is Christine, and I’ll be your conference operator today. At this time, I would like to welcome everyone to TransAlta Corporation Second Quarter 2018 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. [Operator Instructions] Thank you.
RNW TAC TRSWF

 
TAC / TransAlta Corporation FORM 6-K (Current Report of Foreign Issuer)

2018-08-03 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TAC

 
TAC / TransAlta Corporation 6-K (Current Report of Foreign Issuer)

2018-08-03 sec.gov
Document FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TAC

 
TAC / TransAlta Corporation FORM 6-K (Current Report of Foreign Issuer)

2018-07-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TAC

 
TAC / TransAlta Corporation FORM 6-K (Current Report of Foreign Issuer)

2018-07-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TAC

 
TAC / TransAlta Corporation FORM 6-K (Current Report of Foreign Issuer)

2018-07-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COM
TAC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TAC / TransAlta Corporation on message board site Silicon Investor.

Heart Attacks, Cancer and strokes. Preventative approaches Heart Attacks, Cancer and strokes. Preventative approaches Heart Attacks, Cancer and strokes. Preventative approaches US Government Attack on Gibson Guitar US Government Attack on Gibson Guitar US Government Attack on Gibson Guitar
Attack Iraq? Attack Iraq? Attack Iraq? Terrorist Attacks -- NEWS UPDATES ONLY Terrorist Attacks -- NEWS UPDATES ONLY Terrorist Attacks -- NEWS UPDATES ONLY
Attack on Iran Imminent? Attack on Iran Imminent? Attack on Iran Imminent? Stock Attack II - A Complete Analysis Stock Attack II - A Complete Analysis Stock Attack II - A Complete Analysis
NutaCea NutaCea NutaCea Yukon Gold: ATAC Resources Yukon Gold: ATAC Resources Yukon Gold: ATAC Resources
International Datacasting - Takeover Target? International Datacasting - Takeover Target? International Datacasting - Takeover Target? Terrorism attack on the USA Terrorism attack on the USA Terrorism attack on the USA
CUSIP: 89346D107